Dr. Junaid Arshad
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 149
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME182605 -
Hematology & Oncology Physician
FL license ME182605 -
Medical Oncology Physician
FL license ME182605
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Tucson Campus Tucson, AZ
- Banner-University Medical Center South Campus Tucson, AZ
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 149
- Services billed
- 483
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 277 | 76 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 64 | 46 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 20 | 18 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Miami, FL | 70 |
| Ondansetron Odt (ondansetron) Other prescribers in Miami, FL | 62 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Miami, FL | 37 |
| Potassium Chloride Other prescribers in Miami, FL | 29 |
| Eliquis (apixaban) Other prescribers in Miami, FL | 21 |
| Creon (lipase/protease/amylase) Other prescribers in Miami, FL | 19 |
| Oxycodone Hcl Other prescribers in Miami, FL | 16 |
| Pantoprazole Sodium Other prescribers in Miami, FL | 14 |
| Imatinib Mesylate | 12 |
| Lorazepam Other prescribers in Miami, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 13 payments worth $14,888 in total to this clinician.
| Boehringer Ingelheim International GmbH | $6,990 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $4,920 |
| Daiichi Sankyo Inc. | $1,501 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $740 |
| Exelixis Inc. | $518 |
| Amgen Inc. | $143 |
| Novartis Pharmaceuticals Corporation | $48.50 |
| AbbVie Inc. | $27.59 |
| Consulting Fee | $14,028 |
|---|---|
| Food and Beverage | $861 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jun 2, 2025 | Consulting Fee IMFINZI · Oncology | $4,920 |
| Boehringer Ingelheim International GmbH Nov 11, 2025 | Consulting Fee | $2,590 |
| Boehringer Ingelheim International GmbH Apr 11, 2025 | Consulting Fee | $2,200 |
| Boehringer Ingelheim International GmbH Jul 15, 2025 | Consulting Fee | $2,200 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee | $1,378 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 31, 2025 | Consulting Fee | $740 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $689,901 in research payments for these studies, mostly to the institutions running them.
- A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarci…
Merck Sharp & Dohme LLC - Expanded Access use of IMDELLTRA in a 35-year-old patient who was diagnosed with DLL3+ pancreatic neuroendocrine carcinoma
Amgen Inc. - A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-…
Merck Sharp & Dohme LLC - A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Ad…
Merck Sharp & Dohme LLC - A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC
Genentech, Inc. - CHS38802
Coherus Oncology, Inc. - A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.